MKMarina V. Khrapova

Marina V. Khrapova

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Marina V. Khrapova has a total of 71 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Comparative assessment of the cytotoxicity of Nrf2-dependent signaling pathway modulators: the role of hormetic protective effect in Parkinson’s disease modeling in vitro

    by A. V. Chechushkov, A. E. Serykh, M. V. Khrapova, E. S. Petrova, P. M. Kozhin, N. V. Kandalintseva, E. B. Menshchikova, А. В. Чечушков, А. Е. Серых, М. B. Храпова, et al.

    In the context of neurodegenerative diseases, one of the most pressing problems of modern medicine, neurohormesis – the mechanism by which the brain responds to low-intensity subtoxic stressors – deserves special attention. The aim of this study was to determine the concentration-dependent effects of inducers and inhibitors of the Keap1/Nrf2/ARE system on the proliferative activity of SH-SY5Y cells under conditions of a parkinsonism-like state induced by the neurotoxin MPP⁺. Material and methods.  Human SH-SY5Y neuroblastoma cells were cultured according to standard procedures. For experiments, cells were seeded into 96-well culture plates at a density of 10 4 cells per well. After 24 h, inducers of the Keap1/Nrf2/ARE system (sulforaphane, original monophenols sodium 3-(3’- tert -butyl-4’-hydroxyphenyl)propyl thiosulfate (TS-13) and sodium 3-(3’- tert -butyl-4’-hydroxyphenyl)propyl selenosulfate (SeS-13)) or an inhibitor (brusatol) were added to the corresponding wells. To model the parkinsonism-like state, 24 h later serial dilutions of the neurotoxin MPP+ were added to the culture and incubated for 16 h. The effect of the compounds on proliferation was determined after 72 h using a resazurin assay. Results and discussion.  The obtained results demonstrate the uniqueness of TS-13, which combines high neuroprotective activity in an in vitro model of Parkinson’s disease with an exceptional safety profile. The analogue of TS-13 in which the divalent sulfur atom in the para -propyl substituent is replaced by selenium (SeS-13) is somewhat more effective as a protective agent; however, its significantly higher intrinsic cytotoxicity limits its applicability. In contrast, sulforaphane, a classical Nrf2 activator, did not show a protective effect, which is likely due to the fact that its optimal protective concentration nearly coincides with the threshold of its own cytotoxicity, and in the experiment it acted at the edge of toxicity. Finally, the Nrf2 inhibitor brusatol, which enhances the degradation of this transcription factor, not only failed to protect the cells but, at higher concentrations, potentiated MPP⁺ toxicity. Taken together, these data indicate that the neuroprotective action of TS-13 and SeS-13 in the MPP⁺-induced toxicity model is mediated by activation of the Keap1/Nrf2/ARE system, and the dose-response curve exhibits a bell-shaped (hormetic) character.

  • Open Access

    Combined administration of synthetic monophenol TS-13 with doxorubicin enhances the antimitotic effect and mitigates adverse effects of the cytostatic in tumor growth model

    by A. E. Serykh, M. V. Khrapova, E. S. Petrova, L. P. Romakh, N. V. Kandalintseva, E. B. Menshchikova

    Chemotherapy toxicity and tumor chemoresistance remain major challenges in modern oncology. One promising strategy to improve therapeutic efficacy and reduce adverse effects is the use of redox-active compounds that attenuate oxidative stress, in particular by activating the antioxidant-responsive Keap1/Nrf2/ARE signaling pathway. The aim of this study was to evaluate the effects of the synthetic monophenol TS-13, which exhibits both direct and indirect antioxidant activity, on the development and metastasis of Lewis lung carcinoma in mice. Material and methods . A total of 106 female C57BL mice were randomized into 12 groups. For one month, some groups received oral administration of TS-13 or the reference compound tert-butylhydroquinone (tBHQ) (100 mg/kg). Subsequently, selected groups were implanted intramuscularly with 2×105 Lewis lung carcinoma cells. Some animals then received two injections of doxorubicin (total dose 8 mg/kg). After 7 weeks, tumor and lung tissues were processed for standard histological analysis. Tumor growth activity was assessed by counting mitotic figures, and the general morphological characteristics of tumor and lung tissues were described. Results. Both doxorubicin and TS-13 demonstrated marked antimitotic effects, which were further enhanced by their combined administration. Combination therapy with cytostatic and TS-13 more effectively suppressed metastatic activity and reduced the overall area of tumor lesions in the lungs compared to monotherapy with doxorubicin, TS-13, or tBHQ. Administration of either TS-13 or tBHQ equally inhibited the development of lung metastases, reducing the number of tumor cells and the formation of large metastatic foci. Notably, the use of TS-13 in combination with doxorubicin partially restored the integrity of the bronchial epithelium. Conclusions . The synthetic monophenol TS-13, acting as both a direct antioxidant and an activator of the Keap1/Nrf2/ARE pathway, demonstrates potential for optimizing anticancer therapy by enhancing the effect of doxorubicin and suppressing tumor growth and metastasis. In addition, its combined use with doxorubicin helps reduce tissue damage and mitigates the adverse impact on the bronchial epithelium. These properties of TS-13 highlight its prospects for reducing side effects and improving the efficacy of standard chemotherapy regimens.

  • The dual-action monophenolic antioxidant TS-13 accelerates hair coat restoration in a mouse model of chemotherapy-induced alopecia

    by E. B. Menshchikova, A. E. Serykh, L. P. Romakh, E. S. Petrova, M. V. Khrapova, A. V. Chechushkov, A. S. Oleynik, N. V. Kandalintseva

    Chemotherapy remains a mainstay in the treatment of malignant neoplasms, and the search for strategies to overcome or mitigate its side effects, including hair loss (CIA, chemotherapy-induced alopecia), remains extremely important. Despite the proven role of oxidative stress in the pathogenesis of CIA, the number of studies on the potential use of antioxidants for its prevention and treatment is limited. The aim of the study was to investigate the effect of the monophenol sodium 3-(3′-tert-butyl-4′-hydroxyphenyl) propylthiosulfonate (TS-13), which possesses direct and indirect antioxidant activity, on hair regrowth in mice modeling CIA. Material and methods . The study was performed on 30 outbred mice of both sexes, divided into 4 groups. Group 1 animals served as controls (n = 7). Mice in Group 2 received TS-13 in drinking water at a dose of 100 mg/kg body weight starting 14 days before depilation and throughout the experiment (Group “TS-13”, n = 7). CIA was modeled in mice of Group 3 (Group “CIA”, n = 8) and Group 4 (Group “CIA + TS-13”, n = 8). Animals in Group 4 received TS-13 in drinking water throughout the entire experiment. The backs of all animals were shaved, and the treated areas were depilated. On day 9, mice in Groups 3 and 4 received an intraperitoneal injection of cyclophosphamide solution (120 mg/kg body weight). Subsequently, the backs were photographed every other day, and the obtained images were analyzed. On day 51, the animals were euthanized, organs (liver, heart, left kidney, spleen) were extracted and weighed. Results and discussion . No significant differences in body weight dynamics were observed between the groups during the experiment; only a tendency towards weight loss was detected in males receiving cyclophosphamide on day 17 (p = 0.0662). In mice of the control group and those receiving TS-13 in drinking water, intensive hair growth began on days 11–13 of the experiment, with complete hair regrowth occurring by days 13–15. In animals of the CIA group, the phase of pronounced hair growth was significantly delayed, starting on day 25 and reaching complete regrowth only by day 40. Administration of TS-13 to mice with CIA (Group 4) accelerated the process, although not to the level of the intact control (Group 1, p = 0.015) or the positive control (Group 2, p = 0.002). Rapid hair growth began on day 17, and complete hair regrowth occurred on day 31; the difference compared to Group 3 was statistically significant (p = 0.004). Conclusions. TS-13 administration accelerates hair regrowth in mice with CIA model, although it does not completely abolish cyclophosphamide’s ability to induce hair loss. We consider the latter a positive outcome, indicating that the substance does not negate the key therapeutic effect of antitumor agents – their antiproliferative action.

  • Open Access

    Original synthetic monophenolic antioxidant with combined effect inhibits tumor growth in vivo

    by E. B. Menshchikova, M. V. Khrapova, P. M. Kozhin, A. V. Chechushkov, E. S. Petrova, A. E. Serykh, L. P. Romakh, N. V. Kandalintseva

    Reactive oxygen metabolites and antioxidants, as well as the redox-sensitive signaling Nrf2-dependent pathway, play a dual role in the formation, growth and progression of malignant neoplasms. The aim of the study was to investigate the ability of the original synthetic monophenolic antioxidant of combined action to influence tumor growth in vivo and the side effects of cytostatic use. Material and methods. Lewis lung carcinoma (LLC) was used as an experimental model of malignant growth. The study was performed on 120 female C57Bl/6 mice, which were divided into 12 groups; the animals were weighed weekly. Mice of the corresponding groups received intragastrically a solution of sodium 3-(3′-tert-butyl-4′-hydroxyphenyl)propylthiosulfonate (TS-13) (100 mg/kg body weight), a suspension of tert-butylhydroquinone (tBHQ) or a solvent (0.9% NaCl solution) throughout the experiment. 28 days after the start of TS-13 and tBHQ administration, mice were implanted intramuscularly with a suspension of LLC cells at a dose of 2×105 cells/mouse; on the 7th and 14th days of tumor development, a solution of doxorubicin was administered intraperitoneally twice at a cumulative dose of 8 mg/kg body weight (4/5 LD10). On the 35th day of tumor growth, the animals were removed from the experiment, the tumor was extracted, weighed and its linear dimensions were determined; the tumor mass coefficient and volume were calculated, respectively. The spleen mass coefficient was also estimated. Results and discussion. On the 7th and 14th days of tumor growth, the body weight of animals receiving TS-13 and tBHQ was statistically significantly greater than that of other tumor carriers. Administration of TS-13 to mice inhibited tumor growth as effectively as doxorubicin, and more significantly when used in combination; tBHQ did not exert an independent inhibitory effect, and did not enhance its effect in combination with the cytostatic. Doxorubicin significantly reduced the spleen mass coefficient, while TS-13 and tBHQ statistically significantly reduced the effect of the cytostatic. Monotherapy with doxorubicin was accompanied by hair loss on the dorsal surface (8 animals out of 10), while no alopecia was observed with the combined administration of the cytostatic with TS-13 and tBHQ. Conclusions. Monophenol TS-13, a direct antioxidant and inducer of the Keap1/Nrf2/ARE system, is comparable to doxorubicin in terms of its antitumor effect. The use of TS-13 allows to significantly reduce the negative manifestations associated with malignant growth and the side effects of chemotherapy, such as cachexia, splenotoxity, and alopecia.


  • Open Access

    New synthetic monophenolic antioxidant TS-13 penetrates the blood-brain barrier

    by M. V. Khrapova, O. S. Bryushinina, Yu. G. Zyuzkova, N. V. Kandalintseva, E. B. Menshchikova, Ю. Г. Зюзькова

    TS-13 (sodium 3-(3’-tert-butyl-4’-hydroxyphenyl)propylthiosulfonate) is a synthetic antioxidant that has demonstrated biological effectiveness in numerous studies in modeling pathological conditions in vivo, in particular, in the model of Parkinson’s disease. In order to establish whether these effects are mediated or associated, among other things, with the direct effect of TS-13 on the organs and tissues of animals, in this work, the concentration of TS-13 in rat blood plasma and brain after intragastric administration was determined. Material and methods. After a single intragastric administration of a solution of TS-13 at a dose of 100 mg/kg, biomaterial (blood, brain) was taken for 24 h in male Sprague Dawley stock rats (n = 57). To measure the concentration of a substance in samples, a bioanalytical method was developed and validated using high-performance liquid chromatography with UV detection. Results and discussion. The method of quantitative determination was developed by us for the first time and validated before the study. It has been established that the calculated values of the calibration samples meet the acceptance criteria (have the required accuracy and precision) in the concentration range from 0.05 to 6 µg/ml, R=0.9998. The results of determining TS-13 concentration in rat blood plasma and brain showed that after a single administration per os, the compound enters the blood, where it is detected for 15 h (mean retention time 7.94 h, half-life 7.59 h, elimination constant 0.13 h-1, total clearance 40.1 l/(kg × h)), and also penetrates the blood-brain barrier, quickly entering the brain (maximum concentration is reached after 1 h). The compound has a low affinity for brain tissue (tissue availability 0.32), and therefore its concentration does not reach high values, however, a slow excretion of the substance is observed - the average retention time is 6.56 h, the half-life is 6.43 h, the elimination constant 0.11 h-1. Conclusions. After a single intragastric administration to rats, TS-13 enters the blood, where at least part of it is detected unchanged after 30 minutes, reaching maximum values after 1 hour. Similar kinetics of the substance is characteristic of the brain, where it is found in smaller amounts. Thus, as a result of the study, it was shown that TS-13 penetrates the blood-brain barrier and is able to directly affect brain structures, which, however, does not negate the possibility of an indirect effect mediated by the ability to change the activity of intra- and intercellular signaling systems.


  • Open Access

    The Keap1/Nrf2/ARE system activators do not increase cardiac resistance to long-term ischemia/reperfusion

    by P. M. Kozhin, A. S. Sementsov, S. E. Khrapov, M. V. Khrapova, L. P. Romakh, N. V. Kandalintseva, E. B. Menshchikova

    Oxidative stress is an important mechanism of myocardial damage during ischemia/reperfusion. To investigate the possibility of restoring the redox balance using “indirect” antioxidant effects, the cardioprotective effect Keap1/Nrf2/ ARE system inducers was studied in long-term ischemia/reperfusion in vivo. Material and methods. We used the original synthetic hydrophilic monophenol sodium 3-(3’-tert-butyl-4’-hydroxyphenyl) propyl thiosulfonate (TS-13) and reference drug tert-butylhydroquinone (tBHQ). Male Wistar rats received 100 mg/kg of TS-13 solution (with drinking water) or tBHQ (intraperitoneally) daily for 7 days. Animals of the comparison groups received the corresponding solvents. Local ischemia (45 min, occlusion of the left coronary artery) and reperfusion (120 min) of the heart were simulated in vivo 1 day after last drug administration. The ECG was recorded during ischemia and reperfusion; at the end of reperfusion, the heart was removed, the zone of hypoperfusion and the zone of necrosis were detected. Changes in the expression of the mRNA of Nfe2l2, Nqo1, Hmox1, Gstp1, Rela, and Nfkb2 gene in myocardial tissue were determined by real-time TaqMan PCR. Results and discussion. Pretreatment with TS-13 and tBHQ did not influence the infarct size and the incidence of ventricular arrhythmias. Preliminary administration of tBHQ did not change the genes expression of the studied in myocardial tissue after prolonged I/R. TS-13 administration was accompanied by an increase in the content of the transcripts of the gene that encodes Nrf2 (by 7.64 times) and Nrf2-driven genes Nqo1 (by 6.46 times) and Hmox1 (by 3.63 times); the expression of the Gstp1, Rela, and Nfkb2 genes did not differ from the corresponding values of the control group; compared to animals treated with tBHQ, the expression of the Nfe2l2, Nqo1, Hmox1, Rela, and Nfkb2 genes was 16.23, 4.44, 2.68, 3.17, and 2.64 times higher, respectively. The results obtained cast doubt on the therapeutic importance of the induction of the Keap1/Nrf2/ARE system during prolonged heart ischemia/reperfusion.

  • Open Access

    Toxicity of new monophenolic synthetic activator of Keap1/Nrf2/ARE redox-sensitive signaling system in vitro and in vivo

    by M. V. Khrapova, S. E. Khrapov, A. V. Chechushkov, P. M. Kozhin, L. P. Romakh, A. E. Serykh, S. V. Kholshin, N. V. Kandalintseva, E. B. Menshchikova, C. Е. Храпов

    One of the promising areas of modern pharmacology is the development of «indirect antioxidants» capable of activating redox-sensitive signaling systems, primarily the Keap1/Nrf2/ARE system. Among its chemical inductors is the hydrophilic monosubstituted monophenol (3’-tert-butyl-4’-hydroxyphenyl)sodium propylthiosulfonate (TS-13) in development. The aim of the study was to investigate TS-13 antiproliferative activity against tumor cell line BT-474 in vitro and acute oral toxicity in mice in vivo. Material and methods. The relationship between TS-13 concentration and proliferative activity of human breast ductal carcinoma cell line BT-474 was determined using the MTT test, the IC50 was calculated and compared to the previously obtained for MCF-7 line; results were correlated with the functional properties of cells based on gene expression (in silico GSEA). In vivo acute toxicity was studied in 50 female C57Bl/6J mice, who received a TS-13 solution in distilled water at various doses by intragastric gavage. LD50 obtained experimentally and predicted in silico using the GUSAR web service were compared. Results and discussion. TS-13 inhibited the proliferation of BT-474 cells in a concentration-dependent manner (exponential approximation, IC50 = 59.5 μM) and was 2.2 times more toxic than for MCF-7 cells. This may be due to functional differences between the BT-474 and MCF-7 lines, as evidenced by the GSEA results. The LD50 value established in the in vivo experiment was 936 mg/kg body weight, the obtained value satisfactorily corresponds to the predicted in silico (561 mg/kg), although in reality the compound turned out to be somewhat less toxic than could be expected based on its structure. Conclusions. A study of the acute toxicity of the new water-soluble monophenol TC-13 allows the classification of it as slightly toxic (toxicity rating level 4) according to the Hodge – Sterner scale) or as moderately hazardous (hazard class 3) according to GOST 12.1.007-76.

  • Open Access

    Increased expression of autophagy and Nrf2-dependent signaling pathway genes by new monophenolic antioxidants depends on their structure

    by S. E. Khrapov, P. M. Kozhin, M. V. Khrapova, A. E. Serykh, L. P. Romakh, V. S. Pavlov, A. V. Chechushkov, S. V. Kholshin, N. K. Zenkov, E. B. Menshchikova

    Under certain conditions, both activators and inhibitors of Nrf2-dependent signaling and autophagy can serve as potential agents for the prevention, treatment, and maintenance therapy of cancer, as well as overcoming chemoresistance. We are developing a panel of structurally related synthetic monophenolic compounds, in addition to a direct antioxidant effect, having the ability to affect intracellular signaling pathways and processes, including the above mentioned. Aim of the study was to investigate the relationship between its structure and the ability to influence the expression of autophagy and Nrf2 pathway genes.Material and methods. Five original hydrophilic phenolic structurally related compounds were synthesized; the prototypical inductor of the Keap1/Nrf2/ARE system, monosubstituted phenol tert-butylhydro-quinone (tBHQ), served as a reference substance. We used cultures of murine Lewis lung carcinoma (LLC) and human breast adenocarcinoma MCF-7 cells, with the test compounds at a concentration of 20 gM cells were incubated for 24 hours. Changes in mRNA expression of Nrf2, Nqo1, LC3b, and Sqstm1 genes encoding Nrf2, NAD(P)H:quinone oxidoreductase-1, LC3B, p62/sequestosome-1, respectively, were determined by TaqMan real-time PCR.Results and discussion. Structurally related synthetic monophenols effectively induced the Keap1/Nrf2/ARE system in LLC and MCF-7 cells, increasing the expression of the Nrf2-driven Nqo1 gene, and ambiguously affected the transcription of genes of proteins mediating autophagy: the content of mRNA of the LC3B protein did not change, while the expression of mRNA of the p62 protein, which affects the operation of both systems (processes), is increased only by the action of ortho-monosubstituted phenol with an «active» sulfur atom in the para-propyl substituent TS-13 and its structural analogue TS-12 with a para-substituent shortened by one methylene. It can be assumed that the observed effect either indicates the ability of TS-13 and TS-12 both to induce the Keap1/Nrf2/ARE system and to stimulate autophagy, or reflects a compound-mediated mutually reinforcing cross-activation of these processes.


  • Open Access

    The Oral Delivery of Water‐Soluble Phenol TS‐13 Ameliorates Granuloma Formation in an In Vivo Model of Tuberculous Granulomatous Inflammation

    by Elena B. Menshchikova, Peter M. Kozhin, Anton V. Chechushkov, Marina V. Khrapova, Nikolay K. Zenkov

    The redox‐sensitive signaling system Keap1/Nrf2/ARE is a premier protective mechanism against oxidative stress that plays a key role in the pathogenesis and development of various diseases, including tuberculous granulomatous inflammation. We have previously reported that novel water‐soluble phenolic antioxidant TS‐13 (sodium 3‐(4 ′‐methoxyphenyl)propyl thiosulfonate) induces Keap1/Nrf2/ARE and attenuates inflammation. The aim of this study is the examination of the effect of TS‐13 on tuberculous granulomatous inflammation. BALB/c mice were administered TS‐13 (100 mg kg-1 day-1) through their drinking water starting immediately after Bacillus Calmette‐Guérin (BCG) intravenous injection. Histological changes, production of reactive oxygen species (ROS) (activity of free‐radical oxidation processes), and mRNA expression of Nrf2‐driven, NF‐κB‐, AP‐1‐, and autophagy‐dependent signal pathway genes in the liver and peritoneal exudate were evaluated 30 days later. After the 30th day of infection, the activity of the Keap1/Nrf2/ARE system was decreased and its effector genes entailed increasing ROS production in the liver. Therapeutic intervention with TS‐13 is aimed at activating the Keap1/Nrf2/ARE system that leads to an increase in Nrf2 and Nrf2‐mediated gene expression and a decrease in NF‐κB expression. Changes in these pathways resulted in a decline of ROS production and a decrease in the number and the size of granulomas. In total, the results indicate that the Keap1/Nrf2/ARE system can be an effective pharmacological target in host‐adjunctive treatment of tuberculosis.


  • Open Access

    Synthetic Phenolic Antioxidant TS-13 Suppresses the Growth of Lewis Lung Carcinoma and Potentiates Oncolytic Effect of Doxorubicin

    by E. B. Men’sHchikova, N. K. Zenkov, P. M. Kozhin, A. V. Chechushkov, A. V. Kovner, M. V. Khrapova, N. V. Kandalintseva, G. G. Martinovich

    ROS are important intracellular messengers; their ambiguous role in malignant processes was demonstrated in many studies. The effects of a synthetic phenolic antioxidant sodium 3-(3’-tert-butyl-4’-hydroxyphenyl)propyl thiosulfonate sodium (TS-13) on the tumor growth and oncolytic properties of doxorubicin were studied in the experimental model of Lewis lung carcinoma in mice. In mice receiving TS-13 with drinking water (100 mg/kg), suppression of tumor growth by 32.3% was observed on day 21 after inoculation of Lewis lung carcinoma cells. Two-fold intraperitoneal injections of doxorubicin in a cumulative dose of 8 mg/kg were followed by inhibition of tumor growth by 49.5%. Combined treatment with TS-13 and doxorubicin suppressed the tumor growth by 55.4%. In contrast to doxorubicin, TS-13 inhibited NO generation by peritoneal macrophages. The results show the prospect of studying TS-13 in the context of overcoming drug-resistance of tumors.